ACR Appropriateness Criteria® Pretreatment Staging of Urothelial Cancer: 2024 Update

被引:0
作者
Barker, Samantha J. [1 ,17 ]
Soylu, Esra [1 ]
Allen, Brian C. [2 ]
Auron, Moises [3 ,4 ]
Costa, Daniel N. [5 ]
Gerena, Marielia [6 ]
Lotan, Yair [5 ,7 ]
Rose, Tracy L. [8 ,9 ]
Solanki, Abhishek [10 ,11 ]
Surasi, Devaki Shilpa [12 ,13 ]
Turkbey, Saris [14 ]
Whitworth, Pat, III [15 ]
Oto, Aytekin [16 ]
机构
[1] Univ Minnesota, Minneapolis, MN USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Cleveland Clin, Cleveland, OH 44106 USA
[4] Amer Coll Physicians, Cleveland, OH USA
[5] UT Southwestern Med Ctr, Dallas, TX USA
[6] New York Med Coll, Valhalla, NY 10595 USA
[7] Amer Urol Assoc, Dallas, TX USA
[8] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA
[9] Amer Soc Clin Oncol, Chapel Hill, NC USA
[10] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA
[11] Commiss Radiat Oncol, Maywood, IL USA
[12] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[13] Commiss Nucl Med & Mol Imaging, Houston, TX 77030 USA
[14] NCI, NIH, Bethesda, MD 20892 USA
[15] Belmont Univ, Thomas Frist Jr Coll Med, Nashville, TN USA
[16] Univ Chicago, Chicago, IL USA
[17] 420 Delaware St SE,MMC 292, Minneapolis, MN 55455 USA
基金
美国国家卫生研究院;
关键词
Appropriateness Criteria; appropriate use criteria; AUC; muscle invasive bladder cancer (MIBC); nonmuscle invasive bladder cancer (NMIBC); pretreatment staging; transitional cell carcinoma; upper tract urothelial carcinoma (UTUC); Urothelial carcinoma; INVASIVE BLADDER-CANCER; POSITRON-EMISSION-TOMOGRAPHY; CONTRAST-ENHANCED ULTRASOUND; TRANSITIONAL-CELL CARCINOMA; UPPER URINARY-TRACT; COMPUTED-TOMOGRAPHY; SINGLE-INSTITUTION; BONE-SCINTIGRAPHY; CLINICAL-VALUE; CT UROGRAPHY;
D O I
10.1016/j.jacr.2024.08.022
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Urothelial cancer is the second most common cancer, and cause of cancer death, related to the genitourinary tract. The goals of imaging for pretreatment staging of urothelial cancer are to evaluate for both local and distant spread of the cancer and assessing for synchronous sites of urothelial cancer in the upper tracts and bladder. For pretreatment staging of urothelial carcinoma, patients can be stratified into one of three groups: 1) nonmuscle invasive bladder cancer; 2) muscle invasive bladder cancer; and 3) upper urinary tract urothelial carcinoma. This document is a review of the current literature for urothelial cancer and resulting recommendations for pretreatment staging imaging. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.
引用
收藏
页码:S464 / S489
页数:26
相关论文
共 128 条
  • [1] Preoperative T Categorization and Prediction of Histopathologic Grading of Urothelial Carcinoma in Renal Pelvis Using Diffusion-Weighted MRI
    Akita, Hirotaka
    Jinzaki, Masahiro
    Kikuchi, Eiji
    Sugiura, Hiroaki
    Akita, Ayano
    Mikami, Shuji
    Kuribayashi, Sachio
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2011, 197 (05) : 1130 - 1136
  • [2] American College of Radiology, ACR Appropriateness Criteria Radiation Dose Assessment Introduction
  • [3] Amin MB, 2017, AJCC Cancer staging manual, V8th, P303
  • [4] Amling CL, 2001, CURR PROB CANCER, V25, P219
  • [5] Neurologic complications of bladder carcinoma - A review of 359 cases
    Anderson, TS
    Regine, WF
    Kryscio, R
    Patchell, RA
    [J]. CANCER, 2003, 97 (09) : 2267 - 2272
  • [6] Clinical Value of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in Bladder Cancer
    Apolo, Andrea B.
    Riches, Jamie
    Schoeder, Heiko
    Akin, Oguz
    Trout, Alisa
    Milowsky, Matthew I.
    Bajorin, Dean F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (25) : 3973 - 3978
  • [7] European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-2019 Update
    Babjuk, Marko
    Burger, Maximilian
    Comperat, Eva M.
    Gontero, Paolo
    Mostafid, A. Hugh
    Palou, Joan
    van Rhijn, Bas W. G.
    Roupret, Morgan
    Shariat, Shahrokh F.
    Sylvester, Richard
    Zigeuner, Richard
    Capoun, Otakar
    Cohen, Daniel
    Dominguez Escrig, Jose Luis
    Hernandez, Virginia
    Peyronnet, Benoit
    Seisen, Thomas
    Soukup, Viktor
    [J]. EUROPEAN UROLOGY, 2019, 76 (05) : 639 - 657
  • [8] THE ROLE OF MR IMAGING IN CARCINOMA OF THE URINARY-BLADDER
    BARENTSZ, JO
    RUIJS, SHJ
    STRIJK, SP
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 1993, 160 (05) : 937 - 947
  • [9] Impact of 18 FDG- PET CT in the Management of Muscle Invasive Bladder Cancer
    Bertolaso, Pauline
    Brouste, Veronique
    Cazeau, Anne-Laure
    de Clermont-Gallerande, Henri
    Bladou, Franck
    Cabart, Mathilde
    Lefort, Felix
    Gross-Goupil, Marine
    [J]. CLINICAL GENITOURINARY CANCER, 2022, 20 (03) : 297 - 297.e6
  • [10] Bladder cancer:: can imaging change patient management?
    Beyersdorff, Dirk
    Zhang, Jingbo
    Schoeder, Heiko
    Bochner, Bernard
    Hricak, Hedvig
    [J]. CURRENT OPINION IN UROLOGY, 2008, 18 (01) : 98 - 104